Andreessen Horowitz July 7, 2022
Peter Donnelly, Vineeta Agarwala and Lauren Richardson

Peter Donnelly is a professor of statistical science at the University of Oxford and the CEO of Genomics PLC, which uses large-scale human genetic data to inform healthcare and drug discovery. In this interview he, Lauren Richardson, and a16z general partner Vineeta Agarwala discuss the concept of polygenic risk scores with and how this lets us quantify how much your personal genetic configuration, as a whole, affects your risk for disease.

They explore how our deepening understanding of the genetic components of common diseases, such as diabetes, heart disease, and cancer, is helping empower a shift from ‘sick care’ to risk management and preventative medicine. But first, the conversation begins...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Interview / Q&A, Pharma / Biotech, Trends
Aviv Regev: The Revolution in Digital Biology
Global Inequities In Access To Drugs Costs Millions Of Lives Each Year
STAT+: New, serious safety risk related to MorphoSys’ cancer drug complicates, potentially threatens, Novartis acquisition
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
Why Conflicts Of Interest May Not Be As Bad As You Think (And Besides We All Have Them!)

Share This Article